Drug Trial Radar · NCT00421889
A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment
Last checked: Nov 19, 2026Latest source record: Jul 28, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
80
Actual
Start
Aug 2005
Primary completion
Feb 2009
Study completion Feb 2009
Sponsor
- Lead sponsor
- Valerio TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jan 15, 2007
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study seeks to assess the safety, pharmacodynamics, pharmacokinetics and efficacy of belinostat (PXD101) administered in combination with carboplatin or paclitaxel or both in patients with solid tumours followed by maximum tolerated dose (MTD) expansion (phase II) in ovarian and bladder cancer patients The clinical trial is now in the MTD (phase II) portion of the study enrolling bladder cancer patients. Enrollment of ovarian patients is complete.
Conditions
- Ovarian Cancer
- Epithelial Ovarian Cancer
- Fallopian Tube Cancer
- Bladder Cancer
Interventions
belinostatDrug
PaclitaxelDrug
CarboplatinDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Tolerable Dose (MTD) Belinostat, Part A,Time frame: Cycle 1
- Dose Limiting Toxicities (DLT), Part ATime frame: Cycle 1
Locations
11 sites in 3 countries. Site status is shown where the registry gives one.
Gynecologic Oncology Associates
Newport Beach, California
Research Facility
Orlando, Florida
Hematology and Oncology Specialists, LLC
Covington, Louisiana
Hematology & Oncology Specialists, LLC
Metairie, Louisiana
Greater Baltimore Medical Center
Baltimore, Maryland
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
Women & Infants Hospital of Rhode Island
Providence, Rhode Island
The Finsen Center, Rigshospitalet
Copenhagen, Denmark
Research Facility, Herlev University Hospital
Herlev, Denmark
The Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom
The Royal Marsden NHS Trust
Surrey, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.